INM-901 shows statistically significant reduction in neuroinflammation in long-term Alzheimer's model

InMed Pharmaceuticals Inc.

INM-901 dose-dependently and significantly reduced pro-inflammatory cytokines TNF-α, IL-1β, and INF-γ.
High dose group showed statistically significant reduction in neurodegeneration biomarker NfL in plasma.
mRNA data showed reduction of neuroinflammatory genes GFAP, CD-33, TLR-2 in brain, supporting study results.
Company will complete analyses of receptor engagement, neuritogenesis, and neuroprotection in coming weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.